发明申请
- 专利标题： FORMULATION
-
申请号： PCT/EP2021/058047申请日： 2021-03-26
-
公开(公告)号： WO2021198116A1公开(公告)日： 2021-10-07
- 发明人: SOMMER, Morten , TOFT-KEHLER, Rasmus , TOFT-KEHLER, Anne, Katrine , DITZINGER, Günter , JELLINGSOE, Mads , ANDRES, Philippe , KNOPP, Matthias, Manne
- 申请人： UNION THERAPEUTICS A/S
- 申请人地址： Tuborg, Havnevej 18
- 专利权人： UNION THERAPEUTICS A/S
- 当前专利权人： UNION THERAPEUTICS A/S
- 当前专利权人地址： Tuborg, Havnevej 18
- 代理机构： HGF
- 优先权： GB2004844.3 2020-04-01
- 主分类号： A61K9/00
- IPC分类号： A61K9/00 ; A61K9/08 ; A61K31/609 ; A61K47/40 ; A61P31/00 ; A61P31/04 ; A61P31/14 ; A61P31/16 ; A61P11/00 ; A61P11/06 ; A61P27/02 ; A61K9/0073
摘要：
The invention relates to formulations comprising a halogenated salicylanilide, or a pharmaceutically acceptable salt thereof, and a cyclodextrin. The formulations may be in the form of a liquid formulation, particularly an aqueous formulation, and provide high concentrations of solubilised halogenated salicylanilide. Also disclosed a formulations in the form of powders and aerosols. Also disclosed are the formulations for use in the treatment of bacterial and viral infections, and the treatment of inflammatory diseases. The formulations are particularly suitable for administration by inhalation for the treatment of bacterial and viral pulmonary infections and the treatment of pulmonary inflammatory diseases.
